During the past decade, Patagonia Research conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Patagonia Research" are "Early Breast Cancer" (1 trials) and "Triple Negative Breast Neoplasms" (1 trials). Many other conditions were trialed in "Patagonia Research" in a lesser frequency.

Most popular intervention types in "Patagonia Research" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Capecitabine" (1 trials), "Carboplatin" (1 trials), "Endocrine Therapy of Physician's Choice" (1 trials) and "Gemcitabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Patagonia Research" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Patagonia Research". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Patagonia Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Patagonia Research, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".